Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Top Cited Papers
- 1 September 2013
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 145 (3), 574-582.e1
- https://doi.org/10.1053/j.gastro.2013.05.042
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort StudyJNCI Journal of the National Cancer Institute, 2012
- Epidemic Trends of Obesity with Impact on Metabolism and Digestive DiseasesDigestive Diseases, 2012
- The worldwide diabetes epidemicCurrent Opinion in Endocrinology, Diabetes and Obesity, 2012
- The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysisJournal of Hepatology, 2011
- NASH: A global health problemHepatology Research, 2011
- Current therapeutic strategies in non-alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism, 2011
- A fresh look at NASH pathogenesis. Part 1: The metabolic moversJournal of Gastroenterology and Hepatology, 2010
- The liver and the waistline: Fifty years of growthJournal of Gastroenterology and Hepatology, 2009
- Bile acids: Trying to understand their chemistry and biology with the hope of helping patientsJournal of Hepatology, 2008
- Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2007